Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumorsBertrand Routy, Laurence Zitvogel, Emmanuelle Le Chatelier et al.|Science|2017Cited by 5.4k
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinomaToni K. Choueiri, Laurence Albigès|Annals of Oncology|2020Cited by 457
Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophageAurélie Fluckiger, Vincent Cattoir, Romain Daillère et al.|Science|2020Cited by 382
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensusGiuseppe Curigliano, Uwe G. Liebert, Susana Banerjee et al.|Annals of Oncology|2020Cited by 313
Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trialOlivier Mir, Étienne Minvielle, Marie Ferrua et al.|Nature Medicine|2022Cited by 138